Published in Am J Pathol on February 01, 2002
Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev (2011) 2.48
Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci U S A (2002) 1.81
Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol (2006) 1.42
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol (2003) 1.35
Roles of cPLA2alpha and arachidonic acid in cancer. Biochim Biophys Acta (2006) 1.19
Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner. J Biol Chem (2008) 1.16
Phospholipase signalling networks in cancer. Nat Rev Cancer (2012) 1.10
Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs (2005) 1.06
Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. Carcinogenesis (2010) 0.95
Secretory phospholipase A₂ responsive liposomes. J Pharm Sci (2011) 0.92
Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer. Prostate (2011) 0.89
Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int J Nanomedicine (2014) 0.88
Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia (2008) 0.88
Molecular basis of phospholipase A2 activity toward phospholipids with sn-1 substitutions. Biophys J (2007) 0.86
Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules. BMC Cancer (2011) 0.86
Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. Prostate (2010) 0.84
Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease. Biochem Pharmacol (2014) 0.82
Synthesis of lipids for development of multifunctional lipid-based drug-carriers. Bioorg Med Chem Lett (2011) 0.82
Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancer. Integr Biol (Camb) (2013) 0.80
Discrimination between adenocarcinoma and normal pancreatic ductal fluid by proteomic and glycomic analysis. J Proteome Res (2013) 0.80
Serum levels of secreted group IIA phospholipase A(2) in benign prostatic hyperplasia and prostate cancer: a biomarker for inflammation or neoplasia? Inflammation (2012) 0.79
Contrasting epistatic interactions between rat quantitative trait loci controlling mammary cancer development. Mamm Genome (2008) 0.79
Effects of the inhibition of cytosolic phospholipase A(2)α in non-small cell lung cancer cells. J Cancer Res Clin Oncol (2012) 0.78
Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells. Mol Pharm (2014) 0.78
PLA2-responsive and SPIO-loaded phospholipid micelles. Chem Commun (Camb) (2015) 0.77
Involvement of epigenetic mechanisms in the regulation of secreted phospholipase A2 expressions in Jurkat leukemia cells. Neoplasia (2008) 0.77
Expression of secreted phospholipase A2-Group IIA correlates with prognosis of gastric adenocarcinoma. Oncol Lett (2015) 0.77
The expression of phospholipase A2 group X is inversely associated with metastasis in colorectal cancer. Oncol Lett (2012) 0.76
The expression and distribution of group IIA phospholipase A2 in human colorectal tumours. Virchows Arch (2010) 0.76
Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins αvβ3, α4β1, and α5β1. J Biol Chem (2014) 0.76
Synergistic effects of secretory phospholipase A2 from the venom of Agkistrodon piscivorus piscivorus with cancer chemotherapeutic agents. Biomed Res Int (2012) 0.76
Haloenol pyranones and morpholinones as antineoplastic agents of prostate cancer. Bioorg Med Chem Lett (2012) 0.76
Cancer stem cell phenotype is supported by secretory phospholipase A2 in human lung cancer cells. Ann Thorac Surg (2014) 0.75
Secretory phospholipase-A2 and fatty acid composition in oral reactive lesions: a cross-sectional study. Cancer Cell Int (2017) 0.75
Expression of Clonorchis sinensis GIIIsPLA2 protein in baculovirus-infected insect cells and its overexpression facilitating epithelial-mesenchymal transition in Huh7 cells via AKT pathway. Parasitol Res (2017) 0.75
Cytosolic phospholipase A2. J Lipid Mediat Cell Signal (1995) 2.21
New insights on mammalian phospholipase A2(s); comparison of arachidonoyl-selective and -nonselective enzymes. FASEB J (1993) 1.70
Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2. J Biol Chem (1997) 1.28
Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate (1991) 1.24
Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer (1994) 1.19
Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells. Cancer (1993) 1.09
Secretion of group 2 phospholipase A2 by lacrimal glands. Invest Ophthalmol Vis Sci (1994) 1.08
Synovial-type (group II) phospholipase A2 human seminal plasma. Andrologia (1994) 1.00
Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. J Urol (1996) 1.00
Synovial type (group II) phospholipase A2 in cartilage. J Rheumatol (1993) 0.98
Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br J Cancer (1991) 0.97
Elevation of serum group II phospholipase A2 in patients with cancers of digestive organs. Res Commun Chem Pathol Pharmacol (1991) 0.96
Expression of group-II phospholipase A2 in malignant and non-malignant human gastric mucosa. Br J Cancer (1993) 0.95
Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas. Int J Pancreatol (1993) 0.94
Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer. Int J Cancer (1997) 0.94
Signal transduction by bFGF, but not TGF beta 1, involves arachidonic acid metabolism in endothelial cells. J Cell Physiol (1991) 0.89
Cytosolic 85-kDa phospholipase A2-mediated release of arachidonic acid is critical for proliferation of vascular smooth muscle cells. J Biol Chem (1997) 0.88
Differential activation of phospholipases during necrosis or apoptosis: a comparative study using tumor necrosis factor and anti-Fas antibodies. J Cell Biochem (1998) 0.88
Effects of dietary menhaden oil and retinyl acetate on the growth of DU 145 human prostatic adenocarcinoma cells transplanted into athymic nude mice. Carcinogenesis (1988) 0.88
Arachidonic acid metabolites in bFGF-, PDGF-, and serum-stimulated vascular cell growth. Exp Cell Res (1994) 0.88
Immunobiology of the Dunning R-3327 rat prostate adenocarcinoma sublines: plasma and tumor effusion prostaglandins. Am J Reprod Immunol Microbiol (1985) 0.87
Failure to activate cytosolic phospholipase A2 causes TNF resistance in human leukemic cells. J Immunol (1998) 0.87
Structure, function and regulation of mammalian phospholipases A2. Adv Second Messenger Phosphoprotein Res (1993) 0.86
Different apoptotic pathways mediated by Fas and the tumor-necrosis-factor receptor. Cytosolic phospholipase A2 is not involved in Fas-mediated apoptosis. Eur J Biochem (1996) 0.86
Alterations in sphingomyelin and fatty acids in human benign prostatic hyperplasia and prostatic cancer. Biomed Biochim Acta (1991) 0.83
The effect of linoleic, arachidonic and eicosapentaenoic acid supplementation on prostacyclin production in rats. Lipids (1994) 0.80
The prostacyclin analogue cicaprost inhibits metastasis of tumours of R 3327 MAT Lu prostate carcinoma and SMT 2A mammary carcinoma. J Cancer Res Clin Oncol (1992) 0.80
5,8,11,14-eicosatetraynoic acid-induced destruction of mitochondria in human prostate cells (PC-3). In Vitro Cell Dev Biol (1992) 0.78
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98
On the practice of dichotomization of quantitative variables. Psychol Methods (2002) 9.18
eIF-4E expression and its role in malignancies and metastases. Oncogene (2004) 5.10
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology (2005) 3.40
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest (2007) 3.01
Effects of computerized guidelines for managing heart disease in primary care. J Gen Intern Med (2003) 2.96
Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell (2008) 2.84
Prevalence and variable detection of proximal colon serrated polyps during screening colonoscopy. Clin Gastroenterol Hepatol (2010) 2.34
Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity? Eur Urol (2007) 2.33
High colonoscopic prevalence of proximal colon serrated polyps in average-risk men and women. Gastrointest Endosc (2011) 2.22
Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer (2004) 2.22
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer. Eur Urol (2012) 2.18
Failure of computerized treatment suggestions to improve health outcomes of outpatients with uncomplicated hypertension: results of a randomized controlled trial. Pharmacotherapy (2004) 2.17
Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer. Am J Surg Pathol (2007) 2.17
Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review. Anal Quant Cytol Histol (2005) 2.14
Impact of pain on depression treatment response in primary care. Psychosom Med (2004) 2.14
An evaluation of DNA yield, DNA quality and bite registration from a dental impression wafer. J Am Dent Assoc (2007) 2.10
Feasibility of omitting cortical renorrhaphy during robot-assisted partial nephrectomy: a matched analysis. J Endourol (2015) 2.05
Words of wisdom: re: multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. Eur Urol (2013) 2.00
OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol (2004) 1.99
Pan-genome sequence analysis using Panseq: an online tool for the rapid analysis of core and accessory genomic regions. BMC Bioinformatics (2010) 1.95
Can computer-generated evidence-based care suggestions enhance evidence-based management of asthma and chronic obstructive pulmonary disease? A randomized, controlled trial. Health Serv Res (2005) 1.91
Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Mod Pathol (2006) 1.87
Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. Adv Mater (2012) 1.86
Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension (2005) 1.85
Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer (2004) 1.85
FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res (2011) 1.80
Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol (2006) 1.80
Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol (2010) 1.79
Ethnic differences in renal responses to furosemide. Hypertension (2008) 1.74
Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol (2010) 1.73
Toward a method of selecting among computational models of cognition. Psychol Rev (2002) 1.72
Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. BJU Int (2009) 1.71
Risk factors for incidence and severity of white spot lesions during treatment with fixed orthodontic appliances. Am J Orthod Dentofacial Orthop (2010) 1.70
Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res (2004) 1.65
Training postgraduate urologists in laparoscopic surgery: the current challenge. J Urol (2002) 1.64
Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol (2008) 1.64
Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res (2005) 1.63
Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol (2010) 1.61
Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol (2008) 1.60
Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst (2009) 1.59
Clinical outcomes for patients finished with the SureSmile™ method compared with conventional fixed orthodontic therapy. Angle Orthod (2011) 1.59
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol (2011) 1.59
Multivariate statistical differentiation of renal cell carcinomas based on lipidomic analysis by ambient ionization imaging mass spectrometry. Anal Bioanal Chem (2010) 1.58
Racial differences in sensitivity of blood pressure to aldosterone. Hypertension (2014) 1.56
Comparison of quality of life measures in heart failure. Nurs Res (2003) 1.54
Natural history of pancreatitis-induced splenic vein thrombosis: a systematic review and meta-analysis of its incidence and rate of gastrointestinal bleeding. HPB (Oxford) (2011) 1.54
The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Hum Pathol (2007) 1.53
Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol (2004) 1.53
Phase I/II trial of high intensity focused ultrasound for the treatment of previously untreated localized prostate cancer. J Urol (2007) 1.53
Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res (2004) 1.53
Soft tissue tumors of the urinary bladder, Part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential. Hum Pathol (2007) 1.52
Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient's pathology and clinical reports. Eur Urol (2010) 1.51
Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol (2012) 1.50
Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry. Anal Chem (2010) 1.48
Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection. J Urol (2013) 1.48
Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol (2009) 1.46
Intensified effect of adiposity on blood pressure in overweight and obese children. Hypertension (2011) 1.46
Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer (2004) 1.45
Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. Anal Quant Cytol Histol (2007) 1.45
Association of Program Directors in Vascular Surgery (APDVS) survey of program selection, knowledge acquisition, and education provided as viewed by vascular trainees from two different training paradigms. J Vasc Surg (2011) 1.43
Heat-killed bacteria induce genome instability in mouse small intestine, liver and spleen tissues. Cell Cycle (2009) 1.43
2009 update on the classification of renal epithelial tumors in adults. Int J Urol (2009) 1.43
Endoloop-assisted laparoscopic partial nephrectomy. J Endourol (2002) 1.42
Evidence supporting the existence of benign teratomas of the postpubertal testis: a clinical, histopathologic, and molecular genetic analysis of 25 cases. Am J Surg Pathol (2013) 1.42
Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol (2007) 1.39
Examining the relationship between operative time and hospitalization time in minimally invasive and open urologic procedures. J Endourol (2014) 1.39
Effect of time to titration to maximum dose of statins on cardiovascular outcomes: a retrospective analysis in high-risk patients. Am J Cardiovasc Drugs (2009) 1.39
Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy. Virchows Arch (2007) 1.39
Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int (2008) 1.36
Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res (2011) 1.35
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol (2003) 1.35
Nondestructive, histologically compatible tissue imaging by desorption electrospray ionization mass spectrometry. Chembiochem (2011) 1.34
OCT4: A sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res (2004) 1.34
Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol (2010) 1.33